Surgical Oncology

 

William G. Cance
M.D.

RESEARCH INTERESTS:

Ongoing Research Support
U10-CA85790-01A1, Dressler (PI) 09/01/01-03/31/06
NIH
”Tumor Markers to Predict Treatment Response in the Elderly Breast Cancer Patient: A Laboratory Companion in the Elderly”
Primary aim of the clinical trial is to compare the effectiveness of standard chemotherapy regimens with a less toxic, single agent, with respect to five-year relapse free survival in women 65 years and older with early stage breast cancer.
Role: Co-PI

5-RO1-CA65910-09-13, Cance  (PI)  07/01/96- 04/30/10, NCI

"Focal Adhesion Kinase Tumor Biology and Therapeutics"
Primary aim of the clinical trial is to define the survival signals that make specific tumor cell lines more resistant to the effects of FAK downregulation.  The identification of these molecular mechanisms will allow the ultimate development of FAK-based therapeutics of human malignancies.
 

T32-CA106493-01, Cance  (PI)  09/28/05- 08/31/10, NCI

"Surgical Oncology Research Training Program" This Surgical Oncology Training Program is designed to attract and train physicians with a clinical background in surgery in a two-year fellowship of basic oncological research.

Prior Awards:

RO1-CA65910-05 , Cance (PI) 07/01/00-6/30/05 NIH
“The Focal Adhesion Kinase – Tumor Biology and Therapeutics Define the survival signals that make specific tumor cell lines more resistant to the effects of FAK downregulation. The identification of these molecular mechanisms will allow the ultimate development of FAK-based therapeutics of human malignancies
Role: PI

1. Ollila, DW, Caudle, AS, Cance, WG, Jin Kim, H, Cusack, JC, Swasey, JE, Calvo, BF: Successful minimally invasive parathyroidectomy for primary hyperparathyroidism without using intraoperative parathyroid hormone assays.  Am J Surg 191(1):52-6, 2006.

2. Smith, CS, Golubovskaya, VM, Peck, E, Xu,,LH, Monia, BP, Yang, X, Cance, WG:  Effect of focal adhesions kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res 15(5):357-62, 2005.

3. Mendenhall, WM, Zlotecki, RA, Hochwald, SN, Hemming, AW, Grobmyer, SR, Cance, WG: Retroperitoneal soft tissue sarcoma.  Cancer 104(4):669-75, 2005.

4. Lark, AL, Livasy, CA, Dressler, L, Moore, DT, Millikan RC, Geradts, J, Iacocca, M, Cowan, D, Little, D, Crave, RJ, Cance, WG: High focal adhesion kinase expression in invasive breast carcinomas is associated with an agressive phenotype.  Mod Pathol  18(10):1289-94, 2005.

5. Golubovskaya, VM, Finch, R, Cance, WG: Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. J Biol Chem 280(26):25008-21, 2005.


6. Lightfoot, HM Jr, Lark, A, Livasy, CA,  Moore, DT, Cowan, D, Dressler, L, Craven, RJ, Cance, WG: Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.  Breast Cancer Res Treat 88(2):109-16, 2004.

7. Livasy, CA, Moore, D, Cance, WG, Lininger, RA: Focal adhesion kinase overexpression in endometrial neoplasia. Appl Immunohistochem Mol Morphol 12(4): 342-5, 2004.

8. Mendenhall, WM, Amos, EH, Rout, WR, Zlotecki, RA, Hochwald,SN, Cance, WG: Adjuvant postoperative radiotherapy for colon cancer. Cancer 101(6): 1338-44, 2004.

9. Garces, CA, Cance, WG:  Neoadjuvant chemotherapy of breast cancer. Am Surg 70(7):565-9, 2004.

10. Golubovskaya, V, Kaur, A, Cance, WG: cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. Biochem Biophys Acta 1678(2-3):4361-71, 2004.

11.  Kurenova, E, Xu, L, Yang, X, Baldwin, A, Craven, R, Hanks, S, Liu, Z, Cance, WG: The focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor interacting protein. Mol & Cell Bio, 24: 4361-4371, 2004.
 

Primary Navigation